Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Authors not listed

West Japan Thoracic Oncology Group · 1999

Abstract

Vinorelbine is currently the standard treatment for elderly patients with advanced non-small cell lung cancer (NSCLC). Docetaxel has also shown promising results against elderly patients in phase II studies. We conducted a randomized phase III trial to evaluate whether docetaxel provided better overall survival than vinorelbine in elderly patients with advanced NSCLC.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Anonymous. (1999). Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer. <em>West Japan Thoracic Oncology Group</em>. https://clinicaltrials.gov/study/NCT00148291
Vancouver
Anonymous. Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer. West Japan Thoracic Oncology Group. 1999.
BibTeX
@misc{anon1999PhaseI, title = {Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer}, author = {Anonymous}, journal = {West Japan Thoracic Oncology Group}, year = {1999}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings